Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Consortium for Advancing Management and Prevention of Cancer in People with HIV

Award Number: UM1CA121947
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/29/2006
PERIOD OF PERFORMANCE END DATE: 08/31/2030

Group Awards By:

View Award Description

Consortium for Advancing Management and Prevention of Cancer in People with HIV - The mission of the AIDS Malignancy Consortium (AMC) is to investigate through clinical trials new treatment and prevention interventions and study the pathobiology of malignancies and their precursors in people living with human immunodeficiency virus (PLWH) in the United States (U.S.) and internationally. The vision of AMC is to reduce incidence, morbidity, and mortality of cancers occurring in PLWH. Since the AMC was established in 1995 (and as of 11/18/24), it has initiated over 97 interventional clinical trials including 10,787 subjects, resulting in 319 publications and 197 abstracts/presentations, and generated evidence that has transformed practice guidelines in the U.S. and low-middle income countries (LMIC) that have a high HIV burden. AMC has established a network of 39 clinical trial sites (including 29 in the U.S, 6 in sub- Saharan Africa, and 4 in Latin America) that are uniquely qualified to carry out its mission, created a network of translational scientists and their research laboratories that support AMC clinical trials, and developed a Career Enhancement Program (CEP) that has fostered a new generation of AMC leaders. AMC has also actively engaged PLWH and cancer survivors in its scientific planning and community outreach in order to better identify the needs of the community, both within the U.S. and globally, as evidenced by the establishment of a Global Community Advisory Board (CGAB) and inclusion of advocates in strategic and protocol planning. AMC has functioned as a single cooperative group since 2005 under the supervision of the Office of HIV- AIDS Malignancies (OHAM) within the Office of the Director of the National Cancer Institute (NCI). This centralized leadership and accountability has helped create a more cohesive structure and uniform approach to group operations and strategic planning. Although AMC focused initially on small pilot, phase I and II trials, the scope of its activities has broadened to include 3 practice-changing randomized phase III trials, including 2 in KS in collaboration with the AIDS Clinical Trials Group (ACTG), and the landmark ANCHOR trial in the U.S. which demonstrated that treatment of anal high-grade squamous intraepithelial neoplasia (HSIL) reduced the incidence of invasive anal cancer, having a profound impact on clinical practice and future research priorities regarding how to most effectively screen for and treat high-grade anal HSIL. Despite challenges posed by the Covid-19 pandemic during years 14-18 of the current funding period, AMC launched a new generation of trials that built upon its prior work, increased overall accrual, began new initiatives in cancer control, prevention, and survivorship, expanded its collaborations with other NCI-funded networks, expanded its laboratory network and biorepository program, and expanded its career enhancement program. AMC will continue to developing hypothesis-driven pilot, phase I, I-II, and III trials designed to address its mission and vision.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $22,165,668 )
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	016	20	9/6/2026	SUPPLEMENT FOR EXPANSION	$153,250
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	015	20	9/5/2026	SUPPLEMENT FOR EXPANSION	$163,250
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	014	20	9/4/2026	SUPPLEMENT FOR EXPANSION	$172,472
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	010	20	8/24/2026	NON-COMPETING CONTINUATION	$17,521,356
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	012	20	9/2/2026	SUPPLEMENT FOR EXPANSION	$31,044
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	011	20	9/1/2026	NON-COMPETING CONTINUATION	$4,001,470
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	013	20	9/3/2026	SUPPLEMENT FOR EXPANSION	$122,826
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	007	19	5/15/2026	COMPETING CONTINUATION	$0
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	009	19	7/13/2026	SUPPLEMENT FOR EXPANSION	$0
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	004	19	12/18/2025	SUPPLEMENT FOR EXPANSION	$0
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	19	12/18/2025	SUPPLEMENT FOR EXPANSION	$0
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	008	19	7/13/2026	SUPPLEMENT FOR EXPANSION	$0
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	003	19	12/18/2025	SUPPLEMENT FOR EXPANSION	$0
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	005	19	12/18/2025	SUPPLEMENT FOR EXPANSION	$0
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	19	12/18/2025	SUPPLEMENT FOR EXPANSION	$0
2026	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	002	19	12/18/2025	SUPPLEMENT FOR EXPANSION	$0
2026	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	006	18	3/27/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $22,165,668

Issue Date FY: 2025 ( Subtotal = $18,325,234 )
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	18	12/18/2024	SUPPLEMENT FOR EXPANSION	$78,040
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	003	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$122,856
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	005	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$159,865
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	011	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$276,394
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	006	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$153,250
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	002	19	9/16/2025	SUPPLEMENT FOR EXPANSION	$49,803
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	19	9/15/2025	COMPETING CONTINUATION	$16,392,131
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	004	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$172,472
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	010	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$260,987
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	009	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$208,465
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	007	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$251,897
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	008	19	9/17/2025	SUPPLEMENT FOR EXPANSION	$199,074
														Subtotal = $18,325,234

Issue Date FY: 2024 ( Subtotal = $21,981,720 )
2024	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	18	9/3/2024	NON-COMPETING CONTINUATION	$21,331,737
2024	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	17	4/30/2024	SUPPLEMENT FOR EXPANSION	$649,983
														Subtotal = $21,981,720

Issue Date FY: 2023 ( Subtotal = $22,055,360 )
2023	2023	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	002	17	9/1/2023	NON-COMPETING CONTINUATION	$22,055,360
2023	2022	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	001	16	8/31/2023	NON-COMPETING CONTINUATION	$0
2023	2022	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	000	16	6/15/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $22,055,360

Issue Date FY: 2022 ( Subtotal = $22,098,764 )
2022	2022	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	004	16	8/31/2022	NON-COMPETING CONTINUATION	$22,098,764
2022	2021	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	003	15	5/9/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2022	2021	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	002	15	1/12/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$3,249,492
2022	2020	MONTEFIORE MEDICAL CENTER	111 E 210TH ST	BRONX	NY	10467	BRONX	USA	Cancer Treatment Research	001	14	1/12/2022	SUPPLEMENT FOR EXPANSION	-$149,833
2022	2020	MONTEFIORE MEDICAL CENTER	111 E 210TH ST	BRONX	NY	10467	BRONX	USA	Cancer Treatment Research	000	14	1/12/2022	COMPETING CONTINUATION	-$3,099,659
														Subtotal = $22,098,764

Issue Date FY: 2021 ( Subtotal = $22,174,221 )
2021	2021	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Treatment Research	004	15	9/2/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$22,174,221
2021	2020	MONTEFIORE MEDICAL CENTER	111 E 210TH ST	BRONX	NY	10467	BRONX	USA	Cancer Treatment Research	002	14	4/22/2021	COMPETING CONTINUATION	$3,701,814
2021	2020	MONTEFIORE MEDICAL CENTER	111 E 210TH ST	BRONX	NY	10467	BRONX	USA	Cancer Treatment Research	000	14	4/14/2021	COMPETING CONTINUATION	$0
2021	2020	MONTEFIORE MEDICAL CENTER	111 E 210TH ST	BRONX	NY	10467	BRONX	USA	Cancer Treatment Research	003	14	9/1/2021	COMPETING CONTINUATION	$0
2021	2019	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Cancer Treatment Research	001	13	4/22/2021	NON-COMPETING CONTINUATION	-$3,701,814
														Subtotal = $22,174,221

Grand Total All Awards = $252,190,677

Page 1 of 2 (67 items)12

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Consortium for Advancing Management and Prevention of Cancer in People with HIV

Award Number: UM1CA121947

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/29/2006

PERIOD OF PERFORMANCE END DATE: 08/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer